TTPH Market Cap History
Below is a table of the TTPH market cap history going back to 3/20/2013:

Date TTPH Market Cap
3/20/2013111.80M
4/30/2013209.51M
5/9/2013161.65M
8/1/2013164.34M
11/13/2013266.62M
2/28/2014350.75M
7/31/2014272.51M
11/4/2014726.89M
2/28/20151.22B
5/1/20151.33B
10/30/2015329.98M
2/19/2016176.04M
5/2/2016203.16M
8/2/2016147.16M
11/3/2016119.94M
3/10/2017257.55M
5/4/2017290.37M
8/2/2017315.00M
10/31/2017309.00M
3/2/2018136.30M
8/1/2018150.12M
11/8/2018120.66M
3/12/201966.11M
5/7/201956.98M
8/6/201918.30M
9/27/201915.56M
11/8/20199.62M
3/9/202011.61M
5/6/202010.10M

Also see: TTPH Shares Outstanding History
and TTPH YTD Return
TTPH Historical Market Cap:
-28.61% CAGR
TTPH Historical Market Cap: +-28.61% CAGR

Mouse over chart for data details
3/20/2013 ...5/6/2020
Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize tetracyclines for serious conditions, including bacterial infections caused by multidrug-resistant (MDR) bacteria. Co.'s product, Xerava (eravacycline), is an intravenous, antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections. In addition to Xerava, Co. has also developed other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846, a tetracycline for the treatment of acute myeloid leukemia. We show 29 historical shares outstanding datapoints in our TTPH shares outstanding history coverage, used to compute TTPH market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing TTPH market cap history over the course of time is important for investors interested in comparing TTPH's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of TTPH versus a peer is one thing; comparing TTPH market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like TTPH can fluctuate over the course of history. With this page we aim to empower investors researching TTPH by allowing them to research the TTPH market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for TTPH:
TTPH SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Tetraphase Pharmaceuticals (TTPH) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

TVTY Market Cap History
TXMD Market Cap History
TYME Market Cap History
UHS Market Cap History
USPH Market Cap History
UTHR Market Cap History
UTMD Market Cap History
VAR Market Cap History
VBIV Market Cap History
VCEL Market Cap History
More Healthcare companies »

 

TTPH Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.